Bio Developments

Pic:getty/gilnature

Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.

Pic:getty

Samsung Ventures invests in Araris Biotech in emerging ADC strategy

By Jonathan Smith

Samsung Ventures, the global investment arm of Samsung Group, has invested an undisclosed amount in the Swiss company Araris Biotech. The deal is independent from Araris’ ongoing Series A fundraising and will be used to bankroll the development of antibody-drug...

Pic:getty/drmicrobe

Building an mRNA giant: Moderna’s 7 priorities for 2023

By Rachel Arthur

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...

Pic:getty/richarddrury

BioNTech and OncoC4 team up on novel checkpoint antibody

By Rachel Arthur

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....

Pic:getty/andrejrostek

Novartis releases long-term Zolgensma data

By Rachel Arthur

Novartis has presented new data which ‘underscore the transformational and sustained benefit’ of spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec): with treated children maintaining motor milestones after 7.5 years.

Pic:getty/aventtr

Biotage acquires Astrea Bioseparations

By Rachel Arthur

Biotage will acquire Astrea Bioseparations, a chromatography solutions provider, from Gamma Biosciences: extending its chromatography franchise into the bioprocessing market for biologics and advanced therapeutic customers.

Pic:getty/antoniosolano

Syena sets out to pioneer TCR NK cell therapy

By Rachel Arthur

New company Syena says it has the potential to create the next generation of cell therapy: combining the safety, potency and scalability of natural killer (NK) cells with the ability of T cell receptors (TCR) to target intracellular tumor antigens.

Pic:getty/totojang

CGT Catapult boost for UK life science campus

By Rachel Arthur

The Cell and Gene Therapy Catapult (CGT Catapult) has confirmed its involvement in the development of a new £900m ($1,097m) life science campus in Stevenage, UK: which is set to become one of the largest in Europe.

Follow us

Webinars

Headlines